Petah-Tiqva, Israel

Netaly Khazanov


 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2020-2021

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Netaly Khazanov: Innovator in CFTR Protein Mediated Diseases

Introduction

Netaly Khazanov is a notable inventor based in Petah-Tiqva, Israel. He has made significant contributions to the field of medical research, particularly in the treatment of diseases related to the cystic fibrosis transmembrane conductance regulator (CFTR) protein. With a total of 2 patents, his work is paving the way for innovative therapeutic approaches.

Latest Patents

Khazanov's latest patents focus on the development of 2-amino-N'-benzylideneacetohydrazides and their derivatives for managing CFTR protein mediated diseases. These patents disclose methods for treating or preventing conditions such as cystic fibrosis, chronic obstructive pulmonary disease, chronic pancreatitis, chronic bronchitis, asthma, and mucus formation. The innovative compounds he has developed include specific derivatives that can be administered effectively to subjects in need.

Career Highlights

Throughout his career, Khazanov has worked with prestigious institutions, including Emory University and Bar-Ilan University. His research has been instrumental in advancing the understanding and treatment of CFTR related diseases. His dedication to innovation in this field has garnered attention from both the academic and medical communities.

Collaborations

Khazanov has collaborated with esteemed colleagues such as Nael McCarty and Guiying Cui. These partnerships have further enriched his research and contributed to the development of effective treatments for CFTR mediated diseases.

Conclusion

Netaly Khazanov's contributions to the field of medical research, particularly in the management of CFTR protein mediated diseases, highlight his role as an innovative inventor. His patents and collaborations reflect a commitment to improving health outcomes for patients affected by these conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…